By Ben LevisohnIt’s been a bad, bad week for biotech stocks. The iShares Nasdaq Biotech Index ETF (IBB) had dropped 9.3% this week through Thursday’s close, while Amgen (AMGN), Biogen Idec (BIIB), and Celgene (CELG) also suffered big losses. Evercore ISI’s Mark Schoenebaum notes that the valuations of big biotech companies is trading below that of the S&P 500 for only the […]
Last summer, Federal Reserve Chair Janet Yellen said valuations in certain corners of the stock market like biotech were getting “substantially stretched,” and traders have gotten a good laugh at her warning ever since as the stocks resumed their winning ways and raced higher. But given the recent battering of the biotech stocks, the caution recommended by the central bank […]
Recent sharp gains in the U.S. dollar <.DXY> have increased worries about the currency’s impact on the earnings of U.S. multinationals. S&P 500 earnings projections for the first quarter and for 2015 have fallen sharply since Jan. 1.Among early reporters, Nike (>> Nike Inc) jumped 3.7 percent to $101.98 as the biggest boost to the Dow after it posted a […]
Related BIIBStifel Downgrades Biogen Amid Concerns Of Lack Of Upcoming Data, OvervaluationBenzinga’s Top #PreMarket LosersIs Biogen Stock Worth Considering Right Now?(Seeking Alpha)Related GILDGilead Shares Tumble On Drug Warning; Baird Says BuyBenzinga’s Top #PreMarket LosersSeeking Alpha’s Biotech Weekly: Biogen’s Plaque Attack, Amgen Or Gilead?, And More(Seeking Alpha)A number of biotech stocks were soaring in Friday’s premarket following positive news.Biogen Idec Inc […]
Source: Flickr user Simon & His Camera .Love is in the air, and that makes it the perfect time to confess my affection for three large-cap biotech stocks that market a slate of highly profitable, market-share leading therapies. Read on to learn more about why I have fallen for each of them.No. 1: Celgene CorporationWhile other companies hem and haw […]
A doubling of Gilead Sciences ‘ sales has given investors plenty of reason to cheer on the biotech Goliath over the past year. However, with Gilead Sciences’ sales growth set to slow this year, investors may find that these three top biotech stocks prove to be a better bet in 2015.Source: Biogen Idec: Gilead Sciences’ slowing sales growth this year […]
It isn’t a surprise to most that the biotech names have had a rough start to the year.
Really, March was pretty bad.
However, with the market recovering as of late, many of the beaten up biotech stocks have rebounded somewhat. A lot of analysts believe the rebound will continue.
As an investor, if you agree with those analysts, then it certainly wouldn’t […]
